top of page

Dr. CHIU Wing Yan, Joanne

B.Sc. (Canada), M.Sc. (Canada), MBBS (HK), MRCP (UK), FHKAM (Medicine), FHKCP (Med Onc), PDipID (HK)

Clinical Assistant Professor, Department of Medicine
University of Hong Kong,
Queen Mary Hospital &
Gleneagles Hospital Hong Kong

Dr. Chiu.png


Dr. Joanne Chiu is a specialist in medical oncology. Dr. Chiu received post-graduate education in pharmacology in Canada, and returned to Hong Kong for her medical degree. After completing her specialist training in Queen Mary Hospital, Dr. Chiu pursued a fellowship program in the Drug Development Program at Princess Margaret Cancer Center in Toronto. From 2014 to 2019, she served as the Deputy Medical Director at the Phase 1 Clinical Trials Center at the University of Hong Kong.  She is currently Clinical Assistant Professor at the Department of Medicine at the University of Hong Kong and Gleneagles Hospital Hong Kong.  She is the principle investigator of many Phase 1 to Phase 3 clinical trials in breast cancer, genitourinary cancer, and lung cancer.  Dr. Chiu has special interest in new drug development in breast cancer and immunotherapy. She has been invited to speak in many oversea symposiums, and to serve as advisor for regional oncology meetings.  She is also committee members for professional organizations such as Hong Kong Breast Cancer Foundation, and Breast Oncology Group.

Five Most Representative Publications

1)Yap YS, Chiu J, Ito Y, Ishikawa T, Aruga T, Kim SJ, Toyama T, Saeki T, Saito M, Gounaris I, Su F, Ji Y, Han Y, Gazdoiu M, Masuda N.

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer

Cancer Sci. 2020 Sep;111(9):3313-3326. doi: 10.1111/cas.14554. Epub 2020 Jul 28.

[Citation: -] [IF: 6.72 (JCR 2020)]  

2) Dawood S, Chiu JW, Huang CS, Nag S, Sookprasert A, Yap YS, Md Yusof M.

Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.

Curr Med Res Opin. 2020 Aug;36(8):1363-1373. doi: 10.1080/03007995.2020.1783646. Epub 2020 Jul 2.PMID: 32544344

[Citation: -] [IF: 2.58 (JCR 2020)]  

3) Chiu JW, Leung R, Tang V, Cheuk WY, Lo J, Kwok GW, Wong H, Suen D, Cheung P, Wong TT, Yau T, Kwong A.
Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy.
Postgrad Med J 2019; 95(1121):155-161.

[Citation: 1 ] [IF: 1.91 (JCR 2019)]

4) Iwata H, Masuda N, Kim SB, Inoue K, Rai Y, Fujita T, Chiu J, Ohtani S, Takahashi M, Miyaki T, Lu YS, Xu B, Yap YS, Bustam A, Yao B, Zhang B, Bryce R, Chan A.

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.

Future Oncol. 2019 Jul;15(21):2489-2501. doi: 10.2217/fon-2019-0143. Epub 2019 May 29.PMID: 31140297 Clinical Trial.

[Citation: 5 ] [IF: 2.66 (JCR 2019)]

5) Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, Yu C, Kamel-Reid S, Siu LL, Bedard PL, Chen EX.
Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.

Clin Colorectal Cancer. 2018 Mar;17(1):73-79. doi: 10.1016/j.clcc.2017.10.010. Epub 2017 Oct 23.PMID: 29128266

[Citation: 15] [IF: 3.18 (JCR 2018)]

Research Grant Awards

Hong Kong Research Grants Council

General Research Fund (2019 /20 ) –Enhanced immunotherapy strategy for non-small cell lung cancer (NSCLC) harbouring targetable mutation and failed standard tyrosine kinase inhibitors - a phase 2 open-label single-arm study to evaluate the combination of pembrolizumab, lenvatinib and chemotherapy in NSCLC  [Role: Co-I]

bottom of page